Portuguese Italian Spanish English French German
Home: The Catherine Ditman Group
A Network of Tax & Finance Professionals
services

THE USE OF HEMATOPOIETIC GROWTH FACTORS IN CHILDREN WITH CANCER: INDICATIONS AND CONTRAINDICATIONS

A.     Proven indications

When the planned chemotherapy for a nonmyeloid malignancy is likely to result in an ANC < 500 cells/uL for 7 or more days

To accelerate myeloid recovery after chemotherapy in patients with myeloid malignancy and expected ANC < 500 cells/pL for 7 or more days

To accelerate myeloid recovery in patients who have undergone bone marrow transplantation after conditioning drugs have been given

To mobilize peripheral blood stem cells for autologous bone marrow transplantation

B.     Controversial indications

When a prior cycle of the anticipated chemotherapy has been associated with at least one episode of fever and neutropenia

When an ANC of < 500 cells/uL for 7 days or more is anticipated, secondary to noncytotoxic myelosuppressive agents (e.g., ganciclovir, zidovudine)

To increase the granulocyte count in patients with aplastic anemia.

To treat myelodysplastic syndromes associated with an ANC <500 cells/uL.

To treat fever and neutropenia (ANC <500 cells/pL) in patients not yet receiving rhG-CSF. This might be especially important if the patient has signs of sepsis.

C.     Inappropriate indications

Neutropenia secondary to chemotherapy likely to result in an ANC < 500 cells/uL for < 7 days

Infection without neutropenia (ANC > 1000 cells/uL).

Neutropenia (ANC < 1000 cells/mm3) secondary to radiation therapy

To mature or cycle myeloid blasts for better chemotherapeutic response to therapy

D.     Contraindication

History of hypersensitivity to rhG-CSF or Escherichia coli-derived proteins.

*25\168\2*

Cancer

About Us
Testimonials
Contact Us
News
Home
 


<
продажа картона в москве, оао .